Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
EGLN3	112399	ROXADUSTAT	CHEMBL2338329	inhibitor	TdgClinicalTrial, ChemblInteractions, DrugBank
EGLN3	112399	CHEMBL426560	CHEMBL426560		TdgClinicalTrial
EGLN3	112399	ASCORBATE	CHEMBL196		DrugBank	17139284, 17016423
EGLN3	112399	DAPRODUSTAT	CHEMBL3544988	inhibitor	ChemblInteractions

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
EGLN3	rs1629140	A	anthracyclines and related substances	efficacy	no	Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction.	Allele A is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele G.	26100253	1447813829